N-acetyl-β-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment

British Journal of Rheumatology

Volumn 36, Issue 1, 1997, Pages 59-63

  Wiland, P ^a   Swierkot J ^a   Szechinski J ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Methotrexate; N acetyl D glucosaminidase (NAG); Rheumatoid arthritis; Urine albumin

Indexed keywords

ALBUMIN; ANTIRHEUMATIC AGENT; METHOTREXATE; N ACETYL BETA GLUCOSAMINIDASE;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE DURATION; ENZYME ACTIVITY; FEMALE; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; MALE; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RHEUMATOID ARTHRITIS; URINARY EXCRETION;

ACETYLGLUCOSAMINIDASE; ADULT; AGED; ALBUMINURIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CREATININE; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY TUBULES, PROXIMAL; MALE; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; URIC ACID;

EID: 0030746173     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Mandel MA. The synergistic effect of salicylates on methotrexate in man. Plast Reconstruct Surg 1976;57:733-7.
2. Combe B, Edno L, Lafforgue P, Bolgona C et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol 1995;34:421-8.
3. Ahern M, Booth J, Loxton A, McCarthy P, Meffin P, Kevat S. Methotrexate kinetics in rheumatoid arthritis: Is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol 1988;15:1356-60.
4. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of salicylate, ibuprofen and naproxen on the disposition of methotrexate in rheumatoid arthritis. Eur J Clin Pharmacol 1992;42:121-5.
5. Bleyer WA. Methotrexate: Clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977;4:87-101.
6. Diener U, Knoll E, Langer B, Rautenstrauch H, Ratge D, Wisser H. Urinary excretion of NAG and alaninoaminopeptidase in patients receiving amikacin or cisplatinum. Clin Chim Acta 1981;112:149-57.
7. Whiting PH, Nicholls AJ, Catto GRD, Edward N, Engeset J. Patterns of N-acetylo-beta-D-glucosaminidase excretion after renal transplantation. Clin Chim Acta 1980;108:1-7.
8. Wiland P, Szechiński J. N-acetyl-beta-D-glucosaminidase enzymuria as an indicator in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs. Arch Immunol Ther Exp 1994;42:331-6.
9. Price RG, Dance N, Richards B, Cattell WR. The excretion of N-acetyl-beta-D-glucosaminidase and beta-galactosidase following surgery to the kidney. Clin Chim Acta 1970;27:67-72.
10. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-28.
11. Stolarek J, Howey JEA, Fraser CG. Biological variations of urinary N-acetylo-beta-D-glucosaminidase: Practical clinical implications. Clin Chim Acta 1989;35:560-3.
12. Merle LJ, Reidenberg MM, Camacho M et al. Renal injury in patients with rheumatoid arthritis treated with gold. Clin Pharmacol Ther 1980;27:557-62.
13. Wellwood JM, Price RG, Ellis BG, Thompson AE. A note on the practical aspects of the assay of N-acetylo-β-D-glucosaminidase in human urine. Clin Chim Acta 1976;69:85-91.
14. Bird HA, Yu H, Cooper EH. Renal proximal dysfunction in patients with rheumatic diseases. Br Med J 1984;288:1044-5.
15. Malleson PN, Lockitch G, MacKinnon M, Mahy M, Petty RE. Renal disease in chronic arthritis of childhood. Arthritis Rheum 1990;33:1560-6.
16. Sesso R, Neto JT, Ferraz MB, Pereira AB, Ajzen H. Frequent abnormalities of renal function in patients with rheumatoid arthritis. Nephron 1991;59:677-8.
17. Wellwood JM, Ellis BG, Price RG, Hammond K, Thompson AE, Jones NF. Urinary N-acetyl-β-D-glucosaminidase activities in patients with renal disease. Br Med J 1975;3:408-11.
18. Burry HC, Dieppe PA, Bresnihan FB, Brown C. Salicylates and renal function in rheumatoid arthritis. Br Med J 1976;1:613-5.
19. Casadevall G, Moreno JJ, Franch MA, Queralt J. N-acetyl-beta-D-glucosaminidase (NAG) and alanine aminopeptidase (AAP) excretion after acute administration of acetaminophen, salsalate and aspirin in rats. Res Commun Chem Pathol Pharmacol 1993;81:77-89.
20. Proctor RA, Kunin CM. Salicylate induced enzymuria: comparison with other anti-inflammatory agents. Am J Med 1978;65:987-93.
21. 2-microglobulin levels in serum and urine of rheumatoid arthritis patients on gold therapy. Ann Rheum Dis 1981;40:157-60.
22. Henderson ES, Adamson RH, Oliverio WT. The metabolic fate of tritiated methotrexate. II Absorption and excretion in man. Cancer Res 1965;25:1018-24.
23. Leigler DG, Henderson ES, Hahn MA, Oliverio VT. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 1969;10:850-7.
24. Saito M, Uechi Y, Nakabayashi K, Kitamoto K, Nagasawa T. Clinical significance of microalbuminuria in patients with rheumatoid arthritis. Nippon Jinzo Gakkai Shi 1993;35:815-21.
25. Dieppe PA, Doyle DV, Burry HC, Tucker SM. Renal disease in rheumatoid arthritis. Br Med J 1976;1:611-2.